Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 2, 2014, Pages

  Kahle, Erin M ^a   Kashuba, Angela ^b   Baeten, Jared M ^a   Fife, Kenneth H ^c   Celum, Connie ^a   Mujugira, Andrew ^a   Essex, M ^l   De Bruyn, G ^e   Wald, Anna ^a,f   Donnell, Deborah ^f   John Stewart, G ^a   Delany Moretlwe, S ^h   Mugo, Nelly R ^a,i   Farquhar, C ^a   Lingappa, Jairam R ^a,g   Coetzee, D ^j   Fife, K ^k   Were, E ^k   Makhema, J ^l   Katabira, E ^m   Ronald, A ^m   Allen, S ⁿ   Kayitenkore, K ⁿ   Karita, E ⁿ   Bukusi, E ^o   Cohen, C ^o   Kanweka, W ⁿ   Vwalika, B ⁿ   Kapiga, S ^p   Manongi, R ^p   Kiarie, J ^a   Inambao, M ⁿ   Rees, H ^h   Gray, G ^e   McIntyre, J ^e   Rwamba Mugo, N ^a   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c INDIANA UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f USA   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ KENYATTA NATIONAL HOSPITAL   (Kenya)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

^k INDIANA UNIVERSITY   (United States)

^l BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^m MAKERERE UNIVERSITY   (Uganda)

ⁿ EMORY UNIVERSITY   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p HARVARD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; DRUG USE; HETEROSEXUALITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION PREVENTION; INFORMED CONSENT; LABORATORY TEST; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEXUAL TRANSMISSION; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG UTILIZATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84893724076     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a2db02     Document Type: Letter

References (19)

1. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type Rakai Project Study Group. N Engl J Med. 2000;342: 921-929.
2. Gray RJ,Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357: 1149-1153.
3. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5:e12598.
4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. NEngl JMed. 2011;365:493-505.
5. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
6. Lingappa JR, Kahle E, Mugo N, et al. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners Study. PLoS One. 2009;4:e5272.
7. Mujugira A, Baeten JM, Donnell D, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One. 2011;6:e25828.
8. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427-439.
9. Rezk NL, Tidwell RR, Kashuba AD. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2000;791:137-147.
10. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2006 Revision. Geneva, Switzerland: World Health Organization HIV/AIDS Programme; 2006.
11. WHO. Rapid Advice: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Geneva, Switzerland: World Health Organization; 2010. version 2.
12. Muro E, Droste JA, Hofstede HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implication for intervention studies. J Acquir Immune Defic Syndr. 2005;39:419-421.
13. Mackie NE, Fidler S, Tamm N, et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med. 2004;5:180-184.
14. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2004; 37:S2-S12.
15. Grady C. Payment of clinical research subjects. J Clin Invest. 2005;115:1681-1687.
16. Ramjee G, Coumi N, Dladla-Qwabe N, et al. Experiences in conducting multiple communitybased HIV prevention trials among women in KwaZulu-Natal, South Africa. AIDS Res Ther. 2010;7:10.
17. Ruzagira E, Wandiembe S, Bufumbo L, et al. Willingness to participate in preventive HIV vaccine trials in a community-based cohort in south western Uganda. Trop Med Int Health. 2009;14:196-203.
18. Colfax G, Buchbinder S, Vamshidar G, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:359-364.
19. Bentley JP, Thacker PG. The influence of risk and monetary payment on the research participation decision making process. J Med Ethics. 2004;30:293-298.